Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leech thrombin inhibitors.

Michel Salzet1

  • 1Laboratoire de Neuroimmunologie des Annélides, ESA CNRS 8017, SN3,IFR 17 INSERM, Université des Sciences et Technologies de Lille, Villeneuve, 59655 Villeneuve d'Ascq Cédex, France. michel.salzet@univ-lillel.fr

Current Pharmaceutical Design
|April 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.

Molecular cancer·2026
Same author

Cancer, collapse, and the politics of somatic evolution.

Evolution, medicine, and public health·2026
Same author

Toward next-generation machine learning and deep learning for spatial omics.

Briefings in bioinformatics·2026
Same author

Beyond immune privilege: the brain as a dynamic immunological interface.

Cell death & disease·2026
Same author

An expanded reference catalog of translated open reading frames for biomedical research.

Nucleic acids research·2026
Same author

Epithelial-Mesenchymal Transition Shapes the Lipotoxic Response of Colon Cancer Cells to Palmitic Acid.

Molecular & cellular proteomics : MCP·2026
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Serine proteases are involved in diseases and regulated by inhibitors. This review focuses on novel thrombin inhibitors discovered in blood-sucking animals, offering potential therapeutic applications.

Area of Science:

  • Biochemistry and Molecular Biology
  • Enzymology
  • Pharmacology

Background:

  • Serine proteases (SP) play critical roles in physiological processes and are implicated in various clinical disorders, including emphysema, arthritis, and cardiovascular diseases.
  • Natural inhibitors, like anti-thrombin III, regulate serine proteases, particularly thrombin, in normal conditions.
  • Parasitic invertebrates have evolved sophisticated mechanisms to modulate host processes, such as blood coagulation, for survival.

Purpose of the Study:

  • To review the isolation and potential of novel molecules from blood-sucking animals that act as potent inhibitors of the coagulation cascade.
  • To specifically focus on thrombin inhibitors derived from these natural sources.
  • To explore their clinical relevance and therapeutic applications.

Main Methods:

Related Experiment Videos

  • Literature review of studies isolating and characterizing molecules from blood-sucking invertebrates.
  • Analysis of identified molecules targeting coagulation factors, including factor Xa and thrombin.
  • Assessment of inhibitors affecting platelet aggregation.

Main Results:

  • A range of powerful molecules targeting different points of the coagulation cascade have been identified from blood-sucking animals.
  • These molecules include inhibitors of factor Xa, thrombin, and platelet aggregation.
  • Several of these compounds have reached the clinical development stage.

Conclusions:

  • Blood-sucking animals represent a rich source of novel serine protease inhibitors, particularly for thrombin.
  • These naturally derived inhibitors hold significant promise for therapeutic interventions in coagulation-related disorders.
  • Further research into these molecules could lead to new treatments for thrombotic and other diseases.